RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181

Futu News10:31 · Ratings

J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC

Seeking AlphaJan 7 23:27

Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study

WSJJan 7 21:57

Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...

BenzingaJan 7 21:16

Express News | Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib

BreakingsJan 7 21:00

Express News | J&J: Median Overall Survival Improvement With Rybrevant Plus Lazcluze Expected to Exceed One Year

BreakingsJan 7 21:00